SKYE Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.…
Industry Peers
BiotechnologyKey Statistics
About Skye Bioscience (NASDAQ: SKYE)
›
Skye Bioscience (NASDAQ: SKYE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 1.090 USD on 13 November 2026, down 91.0% over 52 weeks. Its 52-week range is 0.5100 USD to 12.16 USD: the price is 91.0% below the high and 113.7% above the low.
Its market capitalisation is 4.83M USD.
Skye Bioscience reports return on equity of -279.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 9.89M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 16 November 2026.